A regenerative medicine company in Vancouver, British Columbia that focuses on treatments for nerve damage and neurodegenerative diseases announced it will begin Phase 1 studies in early 2020 on a new treatment for Alzheimer’s disease.
Subscribe
Login
0 Comments
Oldest
